葡萄糖酸奎尼丁 | 6587-33-3

• 物质功能分类: 原料药 - 循环系统用药 - 抗心律失常药
• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 金鸡纳生物碱
• 中文名称: 葡萄糖酸奎尼丁
• 英文名称: Duraquin
• 英文别名: quinidine gluconate；quinate；quinidine; D gluconate；Chinidin; D-Gluconat；Quinaglute；(S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid
• CAS: 6587-33-3；7054-25-3
• 化学式: C₆H₁₂O₇*C₂₀H₂₄N₂O₂
• 分子量: 520.58
• InChiKey: XHKUDCCTVQUHJQ-LCYSNFERSA-N

物化性质

• 碰撞截面：
  174.9 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

计算性质

• 辛醇/水分配系数(LogP)：
  -0.32
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  184
• 氢给体数：
  7
• 氢受体数：
  11

文献信息

• Mixed steroidal 1, 2, 4, 5- tetraoxane compounds and methods of making and using thereof
  申请人：——

  公开号：US20040019200A1

  公开（公告）日：2004-01-29

  Disclosed herein are mixed steroidal tetraoxanes having the following structural formula 1 1 wherein n is 0, 1, 2, or 3; R is H; ethanoyl, propanoyl, or benzoyl; R1 is H, methyl, ethyl, or isopropyl; R2 is H, methyl, or ethyl; R3 is H, methyl, or ethyl; R4 is H, methyl, ethyl, tert-butyl, phenyl, p-hydroxyphenyl, p-methoxyphenyl, or p-nitrophenyl, or 2 wherein Y is a C 1 -C 4 straight or branched-chain alkoxy, or 3 wherein W is N, R5 is hydrogen, methyl, ethyl, n-propyl, isopropyl, or methyl ethanoate 2-yl, and R6 is hydrogen, methyl, ethyl, or n-propyl, or R5 and R6 are part of a pyrrolidine or piperidine ring; X is a C 1 -C 4 straight or branched-chain alkoxy, a primary amino, a N-alkylamino wherein the alkyl is a straight-chain alkyl groups containing from 1 to 4 carbon atoms, methyl ethanoate-2-yl, N-phenylamino, p-nitrophenyl, N,N-dimethylamino, N,N-diethylamino, N,N-di(n-propyl)amino, N-pyrrolidino, or N-piperidino as single compounds, and any mixture of all possible stereoisomers at C(4″). n may be 0, 1, 2, or 3, and methods of making and using thereof. As disclosed herein, the mixed steroidal tetraoxanes of the present invention exhibit antimalarial, antibacterial, and antiproliferative activity. Thus, as disclosed herein, the mixed steroidal tetraoxanes of the present invention may be used to treat, prevent, or inhibit malaria, bacterial infections, and diseases and disorders associated with cell proliferation in a subject.

  本文披露了具有以下结构式1的混合类固醇四氧杂环戊烷： 1 其中n为0、1、2或3；R为H；乙酰基、丙酰基或苯甲酰基；R1为H、甲基、乙基或异丙基；R2为H、甲基或乙基；R3为H、甲基或乙基；R4为H、甲基、乙基、叔丁基、苯基、对羟基苯基、对甲氧基苯基或对硝基苯基，或 2 其中Y为C 1 -C 4 直链或支链烷氧基，或 3 其中W为N，R5为氢、甲基、乙基、正丙基、异丙基或乙酸甲酯-2-基，R6为氢、甲基、乙基或正丙基，或R5和R6是吡咯烷或哌啶环的一部分；X为C 1 -C 4 直链或支链烷氧基、一级氨基、N-烷基氨基，其中烷基是含有1至4个碳原子的直链烷基，乙酸甲酯-2-基、N-苯基氨基、对硝基苯基、N,N-二甲基氨基、N,N-二乙基氨基、N,N-二(正丙基)氨基、N-吡咯啉基或N-哌啶基作为单一化合物，以及在C(4″)处的所有可能立体异构体的任何混合物。n可以为0、1、2或3，以及其制备和使用方法。如本文所披露的，本发明的混合类固醇四氧杂环戊烷表现出抗疟疾、抗菌和抗增殖活性。因此，如本文所披露的，本发明的混合类固醇四氧杂环戊烷可用于治疗、预防或抑制受试者体内的疟疾、细菌感染以及与细胞增殖相关的疾病和疾病。
• [EN] P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS P2X3 ET/OU P2X2/3 ET MÉTHODES ASSOCIÉES
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2018064135A1

  公开（公告）日：2018-04-05

  The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R7 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.

  本公开提供了新颖的化合物和制备和使用这些化合物的方法。在一种实施例中，这些化合物具有如下式（I）的结构，其中R1-R7在此处定义。在另一种实施例中，这些化合物在调节P2X3或P2X2/3受体中的一种或两种的方法中是有用的。在另一种实施例中，通过向患者施用一种或多种化合物来治疗患者的疼痛是有用的。在另一种实施例中，通过向患者施用一种或多种化合物来治疗患者的呼吸功能障碍是有用的。
• [EN] ANTIBIOTIC COMPOUNDS<br/>[FR] COMPOSÉS ANTIBIOTIQUES
  申请人：DISCUVA LTD

  公开号：WO2018037223A1

  公开（公告）日：2018-03-01

  The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.

  本发明涉及公式（I）的抗生素化合物，含有这些化合物的组合物，以及使用这些化合物治疗细菌性疾病和感染的方法。这些化合物在治疗革兰氏阳性和/或革兰氏阴性细菌引起的感染和疾病方面具有应用，特别是在治疗由淋病奈瑟菌引起的感染和疾病方面。
• [EN] P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS DE P2X3 ET/OU P2X2/3 ET PROCÉDÉS
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2015095128A1

  公开（公告）日：2015-06-25

  The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.

  本申请提供了新颖的化合物以及制备和使用这些化合物的方法。在一个实施例中，这些化合物具有如下式（I）的结构，其中R1-R4在此处被定义。在另一个实施例中，这些化合物在调节P2X3或P2X2/3受体中的一个或两个的方法中是有用的。在另一个实施例中，这些化合物通过向患者施用一个或多个化合物来治疗患者的疼痛是有用的。
• Cyclohexylamines
  申请人：Endo Pharmaceuticals, Inc.

  公开号：US20130101667A1

  公开（公告）日：2013-04-25

  The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.

  本申请提供了新颖的化合物以及制备和使用这些化合物的方法。这些化合物在治疗疼痛、瘙痒、膀胱过度活跃和/或间质性膀胱炎患者中是有用的，通过向患者施用一个或多个这些化合物。这些方法包括给患者施用式(I)的化合物和TRPV1受体激活剂。在一个实施例中，TRPV1受体激活剂是利多卡因。